Obesity Drug Discoveries: what the future holds published by Espicom Business Intelligence in August, 2007. This report consists of 116+ PAGES and the price starts from US $ 1740.
Abstract
While only recently identified as a major health concern, obesity levels have
been growing steadily and the condition threatens to rank among the biggest
causes of premature death in both the industrialised and emerging economies.
With only three products approved worldwide for long-term treatment, and
growing unmet clinical need, the treatment of obesity could present a major
opportunity area for pharma companies.
Obesity has reached epidemic proportions worldwide. With 2005 estimates of
approximately 1.6 billion adults (aged 15 years and over) overweight and at
least 400 million adults obese, the World Health Organization predicts that by
2015, approximately 2.3 billion adults will be overweight and more than 700
million will be obese. These estimates do not even take into account a lower
overweight threshold set for Asians. In the US and Canada half of all adults
are likely to be obese within eight years, with only one in five people of
healthy weight.
The market for weight-loss drugs in the US, Europe and Japan totalled around
US$600 million in 2005, and is expected to rise globally to approximately US$2
billion by 2010. Current long-term treatments include: Abbott' s
Meridia/Reductil (sibutramine), a monoamine reuptake inhibitor that is
approved in the US and Europe; Roche' s Xenical (orlistat), a gastric lipase
inhibitor that is approved in the US and Europe; and sanofi-aventis' Acomplia
(rimonabant), a cannabinoid type 1 receptor blocker that is approved only in
Europe.
No single major company dominates the obesity drug market, although
sanofi-aventis, GSK, Merck & Co and Pfizer all have several compounds in
development. The rewards are high for those who can bring effective treatments
to market, but questions remain...
- What are the strengths and weaknesses for current therapy approaches?
- Which
research approach is likely to achieve best clinical and commercial results
and when are the resulting drugs likely to reach the market?
- What are the
development and regulatory challenges companies must overcome?
The answers to these and many other questions can be found in this new 120+
page strategic management report Obesity Drug Discoveries: What the future
holds (published August 2007). In addition, for those needing to monitor this
developing area there is the Obesity Tracker, an online news service available
for customers buying the web edition of the report.
Key areas addressed
- Sales forecasts for major launched products
- Obesity prevalence and trends
- Detailed appraisal of 20 therapies in research
- Estimation of launch
- Emerging trends and developments
Focus on leading strategies
- Beta3 adrenergic receptor modulators
- Cannabinoid receptor modulators
- Digestive inhibitors/lipid metabolism modulators
- Histaminergic system modulators
- Hormone analogues
- Monoamine reuptake inhibitors/5-HT receptor modulators
- Neuropeptide receptor modulators
- Combination therapies
UNIQUE COMPETITIVE ASSESSMENT SCORE
For each product reviewed, the report provides a critical competitor ratio
analysis, based on our assessment of the following five criteria:
- novelty/rationale for mechanism of action
- proof of concept/clinical data
- management expertise
- competition within the marketplace
- risks associated with drug development in the therapeutic class
Table of Contents
- Foreword
- Executive summary
- What is obesity?
- Defining obesity
- What causes obesity?
- What effects does obesity have?
- Figure 1: Effects of obesity on health
- Table 1. Relative risks of health problems associated with obesity
- The scale of the problem
- Prevalence of obesity
- Figure 2. Estimated global prevalence of obesity
- Highest prevalence of obesity
- Prevalence in the US
- Prevalence in the UK
- Prevalence in Europe
- Prevalence in Asia
- Prevalence in developing countries
- Figure 3. Percentage of households having both underweight and overweight members in seven countries
- Figure 4. Country comparison - percentage of adults with normal BMI
- Childhood and future obesity
- Figure 5. Percentage of population that is overweight
- Figure 6. Predicted prevalence of obesity by 2025
- The economic burden
- US
- UK
- Europe
- Developing Countries
- The obesity therapy market
- Competitor ratio analysis
- Table 2. Competitor ratio analysis summary
- Obesity management
- Controlling energy balance
- Achieving weight loss
- Table 3. The benefits of a 10kg weight loss
- Lifestyle modifications
- Behaviour therapy
- Pharmacotherapy
- Surgery
- Approved drugs for obesity management
- Table 4. History of drug treatments for obesity
- Table 5. Anti-obesity drugs approved for short-term use
- Table 6. Anti-obesity drugs approved for long-term use
- Acomplia
- Approval History
- Key Markets
- Key Agreements
- Clinical Trial Data
- Safety Issues
- Further Development
- Sales
- Sales Forecast
- Figure 7. Acomplia reported and projected sales, 2006A-2012E (EUR million)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Meridia/Reductil
- Approval History
- Key Markets
- Key Agreements
- Clinical Trial Data
- Table 7. Percentage change in subject' s body weight at varying doses
of sibutramine
- Table 8. Health profile of subjects losing at least 5 per cent of
body weight
- Safety Issues
- Further Development
- Xenical/alli
- Approval History
- Key Markets
- Key Agreements
- Patent History
- Clinical Trial Data
- Safety Issues
- Further Development
- Sales
- Sales Forecast
- Figure 8. Reported and projected sales of Xenical 2001A-2011E
- Regulatory authority guidelines for drug approval
- Approval for additional indications
- Potential new drugs
- Table 9. Novel drugs in development by Phase
- Table 10. Novel drugs in development by company
- Drugs in clinical development
- Figure 9. Estimated launch dates for profiled drugs
- Beta3 adrenergic receptor modulators
- Table 11. Beta3 adrenergic receptor modulators in development
- KR P-204 (N-5984)
- Safety Issues
- Competitors
- Launch Prediction
- Cannabinoid receptor modulators
- Table 12. Cannabinoid receptor modulators in development:
- CP-945,598
- Safety Issues
- Competitors
- Launch Prediction
- taranabant
- Safety Issues
- Competitors
- Launch Prediction
- AVE 1625
- Safety Issues
- Competitors
- Launch Prediction
- SLV 319
- Key Agreements
- Safety Issues
- Competitors
- Launch Prediction
- Digestive inhibitors/lipid metabolism modulators
- Table 13. Digestive inhibitors/lipid metabolism modulators in development
- cetilistat
- Key Agreements
- Clinical Trial Data
- Safety Issues
- Further Developments
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- 869682
- Safety Issues
- Competitors
- Launch Prediction
- Histaminergic system modulators
- Table 14. Histaminergic system modulators in development
- OBE 101
- Table 15. Properties of OBE101 and histamine compared
- Key Agreements
- Clinical Trial Data
- Safety Issues
- Table 16. Adverse effects of OBE101 when compared to anti-obesity
medications currently in use
- Patent History
- Further Development
- Competitors
- Launch Prediction
- Hormone analogues
- Table 17. Hormone analogues in development
- pramlintide
- Clinical Trial Data
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- liraglutide
- Clinical Trial Data
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- obinepitide
- Patent History
- Clinical Trial Data
- Further Development
- Safety Issues
- Competitors
- Launch Prediction
- PYY 3-36
- Key Agreements
- Patent History
- Clinical Trial Data
- Further Development
- Safety Issues
- Competitors
- Launch Prediction
- Monoamine reuptake inhibitors/5-HT receptor modulators
- Table 18. Monoamine reuptake inhibitors/5-HT receptor modulators in
development
- lorcaserin
- Patent History
- Clinical Trial Data
- Table 19. Incidence of FDA-defined valvulopathy
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- tesofensine
- Clinical Trial Data
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Neuropeptide receptor modulators
- Table 20. Neuropeptide receptor modulators in development
- S-2367
- Clinical Trial Data
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Combination drugs
- Table 21. Combination drugs in development
- Contrave
- Patent History
- Clinical Trial Data
- Further Developments
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Qnexa
- Clinical Trial Data
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- pramlintide+phentermine/sibutramine
- Safety Issues
- Competitors
- Launch Prediction
- Empatic
- Patent History
- Clinical Trial Data
- Table 22. Percentage change in body weight at week 24
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Recently-terminated programmes
- AMG 076
- AOD 9604
- CP-741952
- CYT 009-GhrQb
- oleoyl-estrone
- Patent History
- Clinical Trial Data
- Further Development
- PF-431499
- The future of obesity treatment
- Towards an all-encompassing cure; targeting the metabolic syndrome?
- Recent advances and future developments
- CD 36
- Targeting ghrelin
- Vaccines
- Gene therapy
- RNA interference
- Conclusions
- Sources
